GLAXO INDIA LTD
Article Abstract:
Glaxo India Ltd (GIL) is a pharmaceutical company. It makes antibiotics, betametasols and vitamins. The contribution of new products to its turnover is less than 5 percent on an year-on- year (YOY) basis. About 60 percent of its products fall under the Drug Pricing Control Order resulting in lesser realisation growth. The merger of Burroughs and Glaxo has been delayed. With Glaxo Wellcome Plc as its new parent, the Indian arm can launch products from the parent's portfolio. This is possible if there is a change in patent laws. The GIL scrip is now trading at Rs393. (uh)
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
DRL VALUES HR AS `INTANGIBLES'
Article Abstract:
Dr Reddy's Laboratories (DRL), a leading pharmaceutical company at Hyderabad, has valued its intangible human resources at Rs88.80 crore for 1997-98. As DRL has termed its human resources as intangible, they will not be shown in the company's balance sheet. DRL has a total workforce of 2,144 employees valued at Rs88.80 crore. It has 277 executives valued at Rs26.50 crore, 804 support staff at Rs20.60 crore, 664 field staff at Rs29.10 crore and 399 factory workers at Rs12.60 crore. (gs)
Comment:
Values intangible human resources at Rs88.80 crore for 1997-98 w/ a total workforce of 2,144 employees
Publication Name: Economic Times
Subject: Business, international
ISSN: 0013-0389
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: JB CHEMICALS: STAY INVESTED FINE DRUGS AND CHEMICALS
- Abstracts: GILADA FINANCE & INVESTMENTS LTD COIMBATORE LAKSHMI INVESTMENT & FINANCE CO
- Abstracts: VISTEON AUTO SYSTEMS MAY ENTER INDIA. CORP HOMES PLANS TO EXPAND OPERATIONS MRF TO EXPAND AUTO COATING NETWORK
- Abstracts: A CHEMISTRY THAT WORKS: GLAXO BULK DRUG SCENARIO. GOVT TURNS DOWN DEMAND TO INCREASE RANITIDINE PRICE
- Abstracts: A CHEMISTRY THAT WORKS: HOECHST MARION ROUSSEL HOECHST SCHERING AGREVO: PROTECTING INVESTORS TOO